KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Retained Earnings (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Retained Earnings for 7 consecutive years, with -$749000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 94.55% year-over-year to -$749000.0, compared with a TTM value of -$749000.0 through Sep 2025, down 94.55%, and an annual FY2024 reading of -$647000.0, up 11.37% over the prior year.
  • Retained Earnings was -$749000.0 for Q3 2025 at Aurinia Pharmaceuticals, up from -$891.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$385000.0 in Q3 2024 and bottomed at -$891.7 million in Q2 2025.
  • Average Retained Earnings over 5 years is -$288.9 million, with a median of -$988000.0 recorded in 2023.
  • The sharpest move saw Retained Earnings tumbled 105473.8% in 2022, then skyrocketed 99.92% in 2023.
  • Year by year, Retained Earnings stood at -$756.1 million in 2021, then decreased by 14.31% to -$864.3 million in 2022, then surged by 99.92% to -$730000.0 in 2023, then grew by 11.37% to -$647000.0 in 2024, then dropped by 15.77% to -$749000.0 in 2025.
  • Business Quant data shows Retained Earnings for AUPH at -$749000.0 in Q3 2025, -$891.7 million in Q2 2025, and -$825000.0 in Q1 2025.